ENTG reports Q2 results today having shed a further 9.4% in yesterday's session alone, bringing the one-month loss to 34% — and every number heading into this print looks more stressed than it did 24 hours ago.
The options market has grown noticeably more defensive into the release. The put/call ratio climbed to 0.47, roughly 1.7 standard deviations above its 20-day average of 0.39, pointing to heavier-than-usual demand for downside protection. That is a measured rather than panicked skew — the 52-week high on the PCR stands at 1.19, so there is room for the hedging to intensify further — but the direction of travel is clear. The borrow market, by contrast, remains completely relaxed. Availability runs near 678%, meaning shares to borrow are plentiful relative to the current short position, and the cost to borrow is a negligible 0.51%. Short interest itself has eased further since yesterday's note: it fell from a peak near 12.8 million shares in early July to around 9.1 million now, or roughly 6% of free float. Shorts are still covering into the fall, not adding. The borrow data reinforces that story — there is no squeeze pressure to speak of.
The analyst community entered this period with a decidedly bullish tilt, though targets now look detached from where the stock is trading. The consensus mean target was $166 as of mid-July — still 55% above the current price of $107. Mizuho had raised its target to $200 and BMO to $167 in early July, both maintaining positive ratings. Goldman Sachs is the notable dissenter, carrying a Sell rating with a $95 target — the only major firm below current levels. The bull case rests on strong purification-solutions demand in the back half of 2026 and an improving gross margin trajectory. Bears counter that the 40% EBITDA flow-through exposes limited operating leverage, and that ENTG's concentrated dependence on the semiconductor equipment cycle makes it acutely vulnerable when the cycle turns. The PE multiple has compressed roughly 14 points over the past month to 27.7x — the market has already done meaningful de-rating work, though forward EPS estimates rank in the 85th percentile for year-on-year growth, a signal that consensus still expects recovery.
The institutional picture adds one notable layer. Capital Research added over 5.3 million shares in the quarter ending June 30, making it the most aggressive buyer among major holders. BlackRock and T. Rowe Price also added during the period. That buying was done at prices well above today's level, which means those holders now face material paper losses — and the question of whether they defend or trim at current levels is an open one. Insider activity through early June showed net selling across several senior executives, with the Executive Chairman alone disposing of over $6.3 million in April.
Today's print is therefore a test of whether ENTG's Q2 revenue and margin trajectory can offer any counter-narrative to a sector selloff that has been indiscriminate — AMKR is down 32% on the week, UCTT 26%, and COHU 24% — and whether the gap between a still-bullish analyst consensus and a sharply lower stock price represents opportunity or denial.
See the live data behind this article on ORTEX.
Open ENTG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
